Selected Medical Interventions in Women With a Deleterious Brca Mutation: A Population-Based Study in British Columbia | Zendy

Gillian E. Hanley | Zendy; Jessica N. McAlpine | Zendy; Rona Cheifetz | Zendy; Kasmintan A. Schrader | Zendy; M. McCullum | Zendy; David G. Huntsman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Selected Medical Interventions in Women With a Deleterious Brca Mutation: A Population-Based Study in British Columbia

Author(s) -

Gillian E. Hanley,

Jessica N. McAlpine,

Rona Cheifetz,

Kasmintan A. Schrader,

M. McCullum,

David G. Huntsman

Publication year - 2019

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.26.4068

Subject(s) - medicine , brca mutation , breast cancer , tamoxifen , gynecology , population , raloxifene , ovarian cancer , prophylactic mastectomy , oophorectomy , mutation , oncology , obstetrics , germline mutation , cancer , mastectomy , hysterectomy , surgery , genetics , environmental health , biology , gene

We examined the uptake of risk-reducing interventions, including bilateral mastectomy, risk-reducing salpingo-oophorectomy, oral contraceptive pills, tamoxifen, and raloxifene, for the entire population of women with a deleterious BRCA1 or BRCA2 mutation in the Canadian province of British Columbia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research